Related Experiment Video
Updated: Jan 26, 2026

Anti-RDL and Anti-mGlutR1 Receptors Antibody Testing in Honeybee Brain Sections using CRISPR-Cas9
Published on: January 30, 2020
Cerebellar disease associated with anti-glutamic acid decarboxylase antibodies: review
José Fidel Baizabal-Carvallo1,2, Marlene Alonso-Juarez3
1Department of Neurology, Parkinson's Disease Center and Movement Disorders Clinic, Baylor College of Medicine, Houston, TX, USA. baizabaljf@hotmail.com.
Abstract:
Several neurological syndromes have been recognized associated to GAD antibodies. Among those disorders, cerebellar ataxia (CA) is one of the most common, along with stiff-person syndrome. Patients with GAD associated CA present with a progressive pancerebellar syndrome, with a subacute or chronic evolution, along with other neurological manifestations such as stiffness, oculomotor dysfunction, epilepsy, and cognitive dysfunction. These symptoms may be preceded by the so-called "brainstem attacks", where manifestations consistent with transient dysfunction of the brainstem may be observed. These patients frequently have extra-neurologic autoimmune manifestations such as diabetes mellitus type 1, polyendocrine autoimmune syndrome, pernicious anemia, vitiligo, etc. A proportion of patients may present with an underlying neoplasia, but the course is less aggressive than in those patients with classical paraneoplastic CA with onconeural antibodies. The diagnosis is based on the present of high serum and CSF titers of GAD antibodies, with intrathecal production of such antibodies. Treatment is aimed to decrease the immunological response with intravenous immunoglobulin, steroids, rituximab and oral immunosuppressive drugs. A subacute presentation and rapid initiation of immunotherapy seem to be the predictors of a favorable clinical response.
Related Concept Videos
Oxidation of Alkenes: Anti Dihydroxylation with Peroxy Acids
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview
Amino acids
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Antiepileptic Drugs: Glutamate Antagonists

